



ASX Announcement

MAYNE PHARMA TO PRESENT AT THE H.C. WAINWRIGHT 26TH ANNUAL GLOBAL INVESTMENT CONFERENCE

5 September 2024, Adelaide, Australia: Mayne Pharma Group Limited (ASX: MYX) today announced that Shawn Patrick O'Brien, Chief Executive Officer of Mayne Pharma, will present at the H.C. Wainwright 26th Annual Global Investment Conference in New York City as follows:

Date: Tuesday, 10 September 2024
Time: 4:30pm US Eastern Time (Wednesday, 11 September 2024 at 6.30am AEST)
Webcast: [Click here](#)

To schedule a 1x1 meeting with the Company, please contact meetings@hcwco.com at H.C. Wainwright.

The live and archived webcast of the presentation will be accessible from the Company's website www.maynepharma.com under Investor Relations. The replay of the webcast will be accessible for 90 days.

For further information contact:

Australia:
Dr Tom Duthy
+61 402 493 727
ir@maynepharma.com

US:
Lisa M. Wilson
+1 917-543-9932
ir@maynepharma.com

Authorised for release to the ASX by the Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.

Mayne Pharma Group Limited

ABN 76 115 832 963

maynepharma.com

1538 Main North Road, Salisbury South, SA 5106 Australia